Aldeyra Therapeutics, Inc. ALDX · Stock Open Aldeyra Therapeutics, Inc. in new tab
Aldeyra Therapeutics, Inc. Analysis (ALDX)
Is Aldeyra Therapeutics, Inc. a good investment? Aldeyra Therapeutics, Inc. (ALDX) is currently trading at 1.53 USD. Market analysts have a consensus price target of 6.60 USD. This suggests a potential upside from current levels.
Earnings Schedule: Aldeyra Therapeutics, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.23.
Investor FAQ
Does Aldeyra Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Aldeyra Therapeutics, Inc.?
Aldeyra Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -0.45.
Company Profile
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Community Discussion